Oncogenic fusion of bcar4 activates egfr signaling and is sensitive to dual inhibition of egfr/her2

HIGHLIGHTS

• who: . and collaborators from the Indian Institute of Technology Indore, Peking University Hospital of have published the Article: Oncogenic fusion of BCAR4 activates EGFR signaling and is sensitive to dual inhibition of EGFR/HER2, in the Journal: (JOURNAL)
• what: The authors aimed to screen a drug library of FDA-approved compounds and subsequently investigate the therapeutic potential of these inhibitors through in_vitro and in_vivo analyses. The authors propose EGFR/ HER2 TKIs as potential inhibitors of CD63-BCAR4 fusion, by demonstrating their inhibitory effects on cell migration and metastasis.
• how: EGFR-TKIs were used . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.